Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Health Behaviour Change

- PMLiVE

Novartis and Kaiku Health expand digital health monitoring partnership

The expansion aims to provide improved cancer care to a wider group of patients spanning multiple indications

- PMLiVE

Pfizer and BioNTech granted FDA Emergency Use Authorisation for BA.4/BA.5 COVID-19 booster

The companies outlined that the original and bivalent vaccines will be supplied under their existing supply agreement with the US government

- PMLiVE

Amgen’s Lumakras shows promising results for patients with non-small cell lung cancer

Results from the phase 3 trial demonstrated superiority over standard of care Docetaxel chemotherapy in KRAS G12C-mutated non-small cell lung cancer

dengue fever mosquito

Manus Bio awarded $2m by Bill & Melinda Gates Foundation to combat malaria

The additional funding will accelerate the development of a production route for artemisinin, a key therapeutic for treating malaria

- PMLiVE

FREE Live Webinar – Overcoming Patient Recruitment Challenges in Rare Disease Trials

Innovative Trials and Pfizer invite you to attend the live webinar

Innovative Trials

- PMLiVE

Novavax’s COVID-19 vaccine candidate approved by MHRA for adolescents aged 12 to 17

Data from an ongoing phase 3 paediatric trial demonstrated Nuvaxovid produced 80% clinical efficacy in this age group

- PMLiVE

Novartis’ Scemblix receives EC approval for chronic myeloid leukaemia

It is estimated that more than 6,300 people will be diagnosed with CML in Europe every year

- PMLiVE

AstraZeneca’s Farxiga data shows ‘significant’ mortality benefits in heart failure patients

The pre-specified pooled analysis from two phase 3 trials demonstrated a reduction in cardiovascular death by 14%

- PMLiVE

BHF announces drug combination could delay need for high-risk surgery in patients with Marfan syndrome

An estimated one million people worldwide live with the genetic condition, for which there is currently no cure

- PMLiVE

Moderna sues Pfizer/BioNTech over COVID-19 vaccine technology

The company believes two key features of its patented mRNA technology platform were copied

- PMLiVE

Novartis to temporarily suspend Huntington’s disease phase 2b study after side effects reported

A data review found that branaplam may cause peripheral neuropathy, which is the result of nerve injury outside the brain and spinal cord

- PMLiVE

Sanofi and Sobi’s efanesoctocog alfa granted FDA priority review for haemophilia A

Phase 3 results showed once-weekly doses provided clinically meaningful bleed protection for patients with haemophilia A

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links